# Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular Carcinoma

> **NCT05701553** · — · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Anti-PD-1/PD-L1
- **DRUG:** S-Adenosyl-Methionine

## Key facts

- **NCT ID:** NCT05701553
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-26
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05701553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05701553, "Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT05701553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*